Allergic Rhinitis Mechanisms and Treatment

被引：283

作者：

Bernstein, David I. ^{[1
]}

Schwartz, Gene ^{[1
]}

Bernstein, Jonathan A. ^{[1
]}

机构：

[1] Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol & Allergy, Cincinnati, OH USA

来源：

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA | 2016年 / 36卷 / 02期

关键词：

Mechanisms; Allergic rhinitis treatment; Leukotrienes; Intranasal corticosteroids; Intranasal antihistamines; Subcutaneous immunotherapy; Treatment; AQUEOUS NASAL SPRAY; PLACEBO-CONTROLLED TRIAL; LEUKOTRIENE RECEPTOR ANTAGONISTS; NUTRITION EXAMINATION SURVEY; UNITED-STATES POPULATION; SKIN-TEST REACTIVITY; 2ND NATIONAL-HEALTH; FLUTICASONE PROPIONATE; SUBCUTANEOUS IMMUNOTHERAPY; MOMETASONE FUROATE;

D O I：

10.1016/j.iac.2015.12.004

中图分类号：

R392 [医学免疫学];

学科分类号：

100108 [医学免疫学];

摘要：

The prevalence of allergic rhinitis (AR) has been estimated at 10% to 40%, and its economic burden is substantial. AR patients develop specific immunoglobulin E (IgE) antibody responses to indoor and outdoor environmental allergens with exposure over time. These specific IgE antibodies bind to high-affinity IgE receptors on mast cells and basophils. Key outcome measures of therapeutic interventions include rhinitis symptom control, rescue medication requirements, and quality-of-life measures. A comprehensive multiple modality treatment plan customized to the individual patient can optimize outcomes.

引用

页码：261 / +

页数：20

共 97 条

[1]

Gluteal Subcutaneous Atrophy After Depot Steroid Injection for Allergic Rhinitis [J].

Ameratunga, Rohan .

WORLD ALLERGY ORGANIZATION JOURNAL, 2012, 5 :168-169

[2]

Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium [J].

Bachert, C ;

van Cauwenberge, P ;

Olbrecht, J ;

van Schoor, J .

ALLERGY, 2006, 61 (06) :693-698

[3]

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis [J].

Baroody, Fuad M. ;

Brown, David ;

Gavanescu, Laura ;

DeTineo, Marcy ;

Naclerio, Robert M. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (04) :927-934

[4]

Systemic Reactions to Subcutaneous Allergen Immunotherapy [J].

Bernstein, David I. ;

Epstein, Tolly .

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2011, 31 (02) :241-+

[5]

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001 [J].

Bernstein, DI ;

Wanner, M ;

Borish, L ;

Liss, GM .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 113 (06) :1129-1136

[6]

Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability [J].

Bernstein, Jonathan A. .

CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (10) :2441-2452

[7]

Progress in the Emergency Management of Hereditary Angioedema: Focus on New Treatment Options in the United States [J].

Bernstein, Jonathan A. ;

Moellman, Joseph J. .

POSTGRADUATE MEDICINE, 2012, 124 (03) :91-100

[8]

Double-blind, placebo-controlled trial of reformulated azelastine nasal spray in patients with seasonal allergic rhinitis [J].

Bernstein, Jonathan A. ;

Prenner, Bruce ;

Ferguson, Berrylin J. ;

Portnoy, Jay ;

Wheeler, William J. ;

Sacks, Harry J. .

AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2009, 23 (05) :512-517

[9]

An algorithm for the management of allergic conjunctivitis [J].

Bielory, Leonard ;

Meltzer, Eli O. ;

Nichols, Kelly K. ;

Melton, Ron ;

Thomas, Randall K. ;

Bartlett, Jimmy D. .

ALLERGY AND ASTHMA PROCEEDINGS, 2013, 34 (05) :408-420

[10]

Allergic rhinoconjunctivitis: Burden of disease [J].

Blaiss, Michael S. .

ALLERGY AND ASTHMA PROCEEDINGS, 2007, 28 (04) :393-397

← 1 2 3 4 5 6 7 8 9 10 →